A Pharmacological Targeting Approach Implementing Albumin As A Carrier Of A Novel Chemotherapeutic
Funder
National Health and Medical Research Council
Funding Amount
$560,659.00
Summary
New drugs for cancer therapy are essential to develop that overcome resistance to standard chemotherapeutics. We have developed potent anti-cancer chelators that bind to the abundant plasma protein, albumin. Our studies showed increased tumour cell uptake of the chelator, Dp44mT, mediated by albumin. We will elucidate the mechanisms of their albumin-mediated uptake, with the aim to implement albumin nanoparticles as carriers of novel chelators to selectively target tumours.
A Pharmacological Targeting Approach Implementing Albumin As A Carrier Of A Novel Chemotherapeutic
Funder
National Health and Medical Research Council
Funding Amount
$428,065.00
Summary
Novel agents that bind essential metals have emerged as a potential avenue for cancer therapy. My laboratory has developed potent anti-cancer agents, such as Dp44mT, that bind to the plasma protein, albumin. Notably, the uptake of Dp44mT into tumour cells was increased in the presence of albumin. My research will examine the mechanisms in the albumin-mediated increase in Dp44mT uptake into tumour cells, with the goal to develop albumin nanoparticles to selectively deliver our agents to tumours.
Overcoming Breast Cancer Heterogeneity And Resistance Using A Novel Therapeutic Approach Targeting The Metastasis Suppressor NDRG1.
Funder
National Health and Medical Research Council
Funding Amount
$431,000.00
Summary
Breast cancer (BrCa) is the leading cause of cancer death in women and current treatments suffer from development of resistance, leading to metastatic progression. I will assess a novel treatment strategy for BrCa, targeting a gene that is able to inhibit multiple key drivers of BrCa, using a novel potent and selective anti-cancer agent. This approach has the potential to overcome resistance to current therapies and alleviate the onset of metastasis, to improve prognosis for BrCa patients.
Targeting Protease Activated Receptor 2 In Immunometabolism And Obesity
Funder
National Health and Medical Research Council
Funding Amount
$720,760.00
Summary
New approaches to prevent and treat obesity and metabolic diseases are National Health Priorities. Obesity is now recognised as an inflammatory disease. This project seeks new biomedical information to verify a new hypothesis that a protein (PAR2) on the surface of fat cells and immune cells is associated with the development of obesity and metabolic disorders.
Improving Cancer Survival By Optimising Drug Exposure At Sites Of Cancer Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$463,652.00
Summary
The metastatic spread of cancer is responsible for 90% of cancer related deaths. While the standard of care is to administer high doses of toxic drugs to kill the cancer, this often leads to life threatening side effects without guarantee of a cure. This work is aimed at identifying how nanometer sized chemotherapeutic ‘nanomedicines’ can be optimally developed to enhance drug targeting towards sites of tumour growth and metastasis and maximise therapeutic success whilst limiting side effects.
Development And Evaluation Of Novel Anti-inflammatory Products Derived From An Indigenous Medicinal Plant
Funder
National Health and Medical Research Council
Funding Amount
$276,598.00
Summary
This collaborative project between researchers at the University of South Australia and Indigenous traditional owners from Northern Kaanju homelands (Cape York Peninsula, Qld) will develop and evaluate products derived from the Northern Kaanju medicinal plant Dodonaea polyandra. Extracts of the plant and novel compounds isolated from it have anti-inflammatory activity. These have the potential to be used in inflammatory diseases such as dermatitis, arthritis and inflammatory bowel disease.
Development of small molecule primary sulfonamides as new drugs for malaria. Malaria is a major global health threat, causing approximately 800,000 deaths annually. Lives can be saved if patients are treated. The use of current antimalarial drugs is limited by drug resistance, low activity and poor safety. This project investigates the effectiveness of a new class of molecule as a safe drug treatment option to kill malaria parasites.
Rational design of new drug candidates for the treatment of Trypanosoma cruzi infection. There is a serious shortage of safe and effective drugs to treat Chagas disease which is caused by a parasitic infection. This project aims to design and identify new drug candidates by defining the disposition profile within the body which is necessary to achieve a therapeutic effect.
Translating pharmacokinetic and pharmacodynamic data to better design new drugs for the treatment of Trypanosoma cruzi infection. New drugs to treat T. cruzi infection are urgently needed, however their design has been hampered by an incomplete understanding of complex host-parasite interactions, inadequate in vitro and in vivo tools to rigorously define activity during drug discovery, and a poor appreciation of concentration/effect relationships. This project aims to develop new and much needed ....Translating pharmacokinetic and pharmacodynamic data to better design new drugs for the treatment of Trypanosoma cruzi infection. New drugs to treat T. cruzi infection are urgently needed, however their design has been hampered by an incomplete understanding of complex host-parasite interactions, inadequate in vitro and in vivo tools to rigorously define activity during drug discovery, and a poor appreciation of concentration/effect relationships. This project aims to develop new and much needed in vitro methods to better define the kinetic and dynamic activity of new drug candidates, and will provide a rational basis for translating this information into lengthy animal models of T. cruzi infection. The outcome aims to be rationally designed drug candidates that are available in a shorter period of time and are suitable for further development.Read moreRead less
Study the Utility of Novel Drug Polymer Conjugates. The products likely to arise from the technology described in this proposal could have application in medical, veterinary and agricultural industries. It offers the potential to treat diseases that are at present poorly treated by enabling delivery direct to the diseased organ (e.g. eye - bacterial endophthalmitis). Completion of the project will also assist a fledgling biotech company transition to a development company with a multiple produ ....Study the Utility of Novel Drug Polymer Conjugates. The products likely to arise from the technology described in this proposal could have application in medical, veterinary and agricultural industries. It offers the potential to treat diseases that are at present poorly treated by enabling delivery direct to the diseased organ (e.g. eye - bacterial endophthalmitis). Completion of the project will also assist a fledgling biotech company transition to a development company with a multiple product portfolio, which will have a direct economic benefit to Australia both in terms of potential export earnings and as an employer highly skilled staff. The project will also provide research training and career opportunities for developing Australian based researchers.Read moreRead less